The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.
Repare Therapeutics, a Canada-based precision cancer therapy developer backed by pharmaceutical firms Bristol Myers Squibb (BMS) and Celgene, will float today in a $220m initial public offering in the US.
The company is issuing 11 million shares on the Nasdaq Global Select Market, having increased that number from 10 million. It priced them at the top of the IPO’s $18 to $20 range. The IPO prices values it at about $700m.
Founded in 2016, Repare is developing targeted cancer drugs…
